Research programme: anti-FGF8 monoclonal antibody - BioWa

Drug Profile

Research programme: anti-FGF8 monoclonal antibody - BioWa

Alternative Names: BIW-7034; BW-8406

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Developer BioWa
  • Class Monoclonal antibodies
  • Mechanism of Action Fibroblast growth factor inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • Available For Licensing Yes - Rheumatoid arthritis; Solid tumours

Highest Development Phases

  • Discontinued Osteoarthritis; Prostate cancer; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 23 Oct 2008 Preclinical development is ongoing in USA
  • 21 Oct 2005 Anti-FGF8 monoclonal antibody has been licensed to BioWa worldwide, except Asia
  • 18 Aug 2005 This programme is still in active development for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top